Clinical Trial Update: PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PUL-042 in patients with parainfluenza virus, human metapneumovirus, or respiratory syncytial virus infections in the setting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Human Metapneumovirus Infection
• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• PUL-042

Snippet

Sponsor: Pulmotect, Inc. | Conditions: Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Status: RECRUITING